58
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Evaluation of Commercially Available Anti–Dengue Virus Immunoglobulin M Tests

      brief-report

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Anti–dengue virus immunoglobulin M kits were evaluated. Test sensitivities were 21%–99% and specificities were 77%–98% compared with reference ELISAs. False-positive results were found for patients with malaria or past dengue infections. Three ELISAs showing strong agreement with reference ELISAs will be included in the World Health Organization Bulk Procurement Scheme.

          Related collections

          Most cited references9

          • Record: found
          • Abstract: found
          • Article: not found

          Dengue in the early febrile phase: viremia and antibody responses.

          A multicenter effort was begun in 1994 to characterize the pathophysiology of dengue using a study design that minimized patient selection bias by offering enrollment to all children with undifferentiated fever for <72 h. In the first year, 189 children were enrolled (age range, 8 months to 14 years). Thirty-two percent of these children had dengue infections (60 volunteers). The percentage of children with a secondary dengue infection was 93%, with only 4 (7%) having a primary dengue infection. The virus isolation rate from the plasma of children with dengue was 98%. Viremia correlated highly with temperature. All four dengue virus serotypes were isolated at both study sites. This study demonstrates that all four serotypes of dengue virus can cause dengue hemorrhagic fever, that all dengue patients as defined by serology experience viremia during the febrile phase, and that as fever subsides, so does viremia.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Dengue diagnosis, advances and challenges.

            Dengue diagnosis was one of the topics discussed at the symposium 'The Global Threat of Dengue - Desperately Seeking Solutions' organized during the 10th International Congress of Infectious Diseases held in Singapore in 2002. In this paper, a review is presented focusing on the main advances, problems and challenges of dengue diagnosis.IgM capture ELISA, virus isolation in mosquito cell lines and live mosquitoes, dengue specific monoclonal antibodies and PCR have all represented major advances in dengue diagnosis. However, an appropriate rapid, early and accessible diagnostic method useful both for epidemiological surveillance and clinical diagnosis is still needed. Also, tools that suggest a prognosis allowing for better management are also needed. Finally, laboratory infrastructure, technical expertise and research capacity must be improved in endemic countries in order to positively influence dengue surveillance, clinical case management and the development of new approaches to dengue control.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Severe dengue virus infection in travelers: risk factors and laboratory indicators.

              Dengue fever is the most common arboviral disease in travelers. In countries where dengue virus is endemic, sequential (secondary) infections with different dengue virus serotypes are associated with disease severity. Data on severity and secondary infection rates in a population of travelers are lacking. Intensified surveillance of dengue fever in travelers was performed within the European Network on Surveillance of Imported Infectious Diseases. Data were collected at 14 European clinical referral centers between 2003 and 2005. A total of 219 dengue virus infections imported from various regions of endemicity were reported. Serological analysis revealed a secondary immune response in 17%. Spontaneous bleeding was observed in 17 (8%) patients and was associated with increased serum alanine and aspartate aminotransferase levels and lower median platelet counts. Two (0.9%) patients fulfilled the World Health Organization (WHO) case definition for dengue hemorrhagic fever. However, 23 (11%) travelers had severe clinical manifestations (internal hemorrhage, plasma leakage, shock, or marked thrombocytopenia). A secondary immune response was significantly associated with both spontaneous bleeding and other severe clinical manifestations. In travelers, severe dengue virus infections are not uncommon but may be missed if the WHO classification is strictly applied. High liver enzyme levels and low platelet counts could serve as indicators of disease severity.
                Bookmark

                Author and article information

                Journal
                Emerg Infect Dis
                EID
                Emerging Infectious Diseases
                Centers for Disease Control and Prevention
                1080-6040
                1080-6059
                March 2009
                : 15
                : 3
                : 436-439
                Affiliations
                [1]Centers for Disease Control and Prevention, San Juan, Puerto Rico, USA (E.A. Hunsperger, K.E. Bessoff)
                [2]Mahidol University, Bangkok, Thailand (S. Yoksan)
                [3]Institut Pasteur, Phnom Penh, Cambodia (P. Buchy)
                [4]Cho Quan Hospital, Ho Chi Minh City, Vietnam (V.C. Nguyen)
                [5]University of Malaya, Kuala Lumpur, Malaysia (S.D. Sekaran)
                [6]Instituto Nacional Enfermedades Virales Humanas Dr. Julio I. Maiztegui, Buenos Aires, Argentina (D.A. Enria)
                [7]Instituto Medicina Tropical Pedro Kouri, Havana, Cuba (S. Vázquez, M.G. Guzmán, J.L. Pelegrino)
                [8]Public Health Agency of Canada, Winnipeg, Manitoba, Canada (H. Artsob, M. Drebot)
                [9]University of Hawaii, Honolulu, Hawaii, USA (D.J. Gubler)
                [10]Pediatric Dengue Vaccine Initiative, Seoul, South Korea (S.B. Halstead, H.S. Margolis, S. Kliks)
                [11]World Health Organization, Geneva, Switzerland (C.-M. Nathanson, N.R. Rizzo, R.W. Peeling)
                Author notes
                Address for correspondence: Rosanna W. Peeling, Special Programme for Research and Training in Tropical Diseases, World Health Organization, 20 Ave Appia, Geneva, Switzerland; email: peelingr@ 123456who.int
                Article
                08-0923
                10.3201/eid1503.080923
                2681117
                19239758
                df9b2fc1-9a01-41e0-8723-d7f3faacf7a2
                History
                Categories
                Dispatch

                Infectious disease & Microbiology
                elisa,immunoglobulin m,dispatch,dengue fever,diagnostic test
                Infectious disease & Microbiology
                elisa, immunoglobulin m, dispatch, dengue fever, diagnostic test

                Comments

                Comment on this article